A Study of LY3041658 in Adults With Hidradenitis Suppurativa

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of LY3041658 in Adults With Moderate-to-Severe Hidradenitis Suppurativa

The reason for this study is to see if the study drug LY3041658 is effective in participants with moderate-to-severe hidradenitis suppurativa (HS).

Inclusion Criteria:

• Have a diagnosis of HS for at least 6 months
• Have HS lesions in at least 2 different anatomic areas
• Have inadequate response or intolerance to a 28 day course of oral antibiotics
• Have a total count of abscesses and inflammatory nodules greater than or equal to 4
• Agree to use a topical antiseptic daily
• Agree to stop using topical antibiotics during the study. In certain cases, oral antibiotics will be allowed

Exclusion Criteria:

• Have more than 20 draining fistulae
• Have received any biologic medication (adalimumab, etc.) for the treatment of HS
• Plan to use oral opioids for HS-related pain during the study
• Uncontrolled depression or suicidal thoughts